- A +

Events › 2015

14 - 17Nov.2015

GenSight Biologics participated to AAO in Las vegas, US.

Jose Alain Sahel MD, CHNO Institut de la Vision, GenSight-Biologics Share Holder and Consultant, gave an oral presentation (Abstract ID: 30043757) : A Recombinant AAV2/2 Vector Carrying the Wild-Type ND4 Gene for the Treatment of Leber Hereditary Optic Neuropathy: Results of a First-in-Human Study on Tuesday, November 17, 2015, 9:30 AM to 9:40 AM, location Bassano 2701. 

 

02 - 04Nov.2015

GenSight attended BioEurope, Munich, Germany, 

and participated to the partnering to meet with a numerous partners and companies, willing to know about our promising products under development and their innovative technologies, to prevent sight loss and restore vision.

17 - 20Sept.2015

GenSight participated to ESGCT Annual meeting. 

Céline Bouquet, Preclinical Manager at GenSight, gave an oral presentation on "Humoral immune response against AAV2/2-ND4 vector (GS010) after intravitreal administration in non-human primates and patients with Leber Hereditary Optic Neuropathy (LHON)" on Friday 18 September, 2015, session S3c Ocular diseases, 4.00-6.00 pm

The ESGCT Annual Meeting provides an opportunity for scientists, clinicians and industry professionals to share new data, learn from peers, and discover global advances within the Gene and Cell Therapy field. With nearly 1,000 participants from 40 countries, the ESGCT Annual Meeting is this year organised in collaboration with the Finnish Society of Gene Therapy.

09 - 12Jul.2015

GenSigth attended ISOPT 2015 in Berlin, Germany.

Jose Alain Sahel MD, CHNO Institut de la Vision, GenSight-Biologics Share Holder and Consultant and Scott Uretsky MD, Neuro-Ophthalmology, Clinical Develoment Director, GenSight-Biologics, gave an oral presentation on : A Recombinant AAV2/2 Carrying the Wild-Type ND4 Gene for the Treatment of LHON: Preliminary Results of a First-In-Man Study and Upcoming Pivotal Efficacy Trials. 

 

21 - 24Jun.2015

GenSight attended EUNOS, 13th congress of European Society for Neuroophthalmology, in Ljubljana, Slovenia

  • Oral presentation : Preliminary safety and tolerability results of an intravitreal injection of rAAV2/2-ND4, a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the human wild-type mitochondrial ND4 gene in patients with LHON due to G11778A mutation
  • Poster : Leber’s Hereditary Optic Neuropathy (LHON): a qualitative study on the experiences and hopes of patients and caregivers.
15 - 17Jun.2015

GenSight attended BIO in Philadelphia, PA, 

and participated to the partnering to meet with a numerous partners and companies, willing to know about our promising products under development and their innovative technologies, to prevent sight loss and restore vision.

05 - 07Jun.2015

GenSight attended the Mitocon conference in June 5, 2015, in Bologna in Italy.

Dr Scott Urestky, MD, Neuro-ophthalmology, Clinical Development Director at GenSight, participated at a rountable within the 4th Session – Therapies – Present and future beside other pharmaceutical companies.

03 - 07May2015

GenSight attended ARVO, Denver (Colorado) and presented 3 posters:

  • Preliminary safety and tolerability results of intravitreal administration of GS010, a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing human wild type mitochondrial NADH dehydrogenase 4 (ND4) gene in patients with LeberHereditary Optic Neuropathy (LHON) due to G11778A mitochondrial DNA mutation.
  • Leber’s Hereditary Optic Neuropathy (LHON): a qualitative study on the experiences and hopes of patients and caregivers.
  • Relevance of NHP safety studies for ocular delivery of AAV-based gene therapy in humans: Example of GS010 (rAAV2/2-ND4) local tolerability, shedding and immunogenicity for the treatment of Leber Hereditary Optic Neuropathy (LHON)), after intravitreal (IVT) injection in non-human primates (NHP) and in LHON patients.
22 - 24Apr.2015

GenSight particpated at the World Orphan Drug Congress in Washington DC,

Jean-Philippe Combal, COO, presented on Friday April 24, at 10.40 am: "Pioneering the development of gene therapy based treatments for retinal degenerative diseases "

12Mar.2015

GenSight participated at the 5th Annual Advanced Therapies Summit, organized by the Alliance for Regenerative Medicine (ARM). Now member of the ARM, GenSight was part of Roundtable II: Gene Therapy in Europe & the U.S.

09 - 11Mar.2015

GenSight attended BioEurope Spring, Paris. GenSight presented in the category Partnerships in Regenerative Medicine and Advanced Therapies and participated at the roundtable: Next-generation treatments in ophthalmology: Can gene and cell-based therapies meet growing expectations for early clinical success?”. 

21 - 26Feb.2015

GenSight attended NANOS, 41st Annual Meeting, in San Diego (CA) and presented:  “Preliminary Safety and Tolerability Results Of A Recombinant Adeno-Associated Viral Vector Serotype 2 (rAAV2/2) Containing The Human Wild-Type Mitochondrial NADH Dehydrogenase 4 (ND4) Gene, In Patients With Leber Hereditary Optic Neuropathy Due To The G11778A Mitochondrial DNA Mutation”

12 - 16Jan.2015

GenSight presented at the 33rd Annual J.P. Morgan Healthcare Conference, San Francisco (CA), on Thursday, January 15, 2015 at 8:00 a.m. PT, room Elizabethan D.